The nuclear entry of the aryl hydrocarbon receptor (AHR) relies on the first nuclear localization signal and can be negatively regulated through IMPα/β specific inhibitors.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
11 11 2023
Historique:
received: 23 05 2023
accepted: 08 11 2023
medline: 13 11 2023
pubmed: 12 11 2023
entrez: 11 11 2023
Statut: epublish

Résumé

The human aryl hydrocarbon receptor (AHR) undergoes continuous shuttling between nucleus and cytoplasm. Binding to exogenous or endogenous ligands promotes its rapid nuclear import. The proposed mechanism for the ligand-dependent import is based on exposing the bipartite nuclear localisation signal (NLS) to members of the importin (IMP) superfamily. Among this, the molecular interactions involved in the basal import still need to be clarified. Utilizing fluorescently fused AHR variants, we recapitulated and characterized AHR localization and nucleo-cytoplasmic shuttling in living cells. Analysis of AHR variants carrying NLS point mutations demonstrated a mandatory role of first (

Identifiants

pubmed: 37951956
doi: 10.1038/s41598-023-47066-z
pii: 10.1038/s41598-023-47066-z
pmc: PMC10640566
doi:

Substances chimiques

Nuclear Localization Signals 0
Receptors, Aryl Hydrocarbon 0
Ligands 0
Karyopherins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

19668

Informations de copyright

© 2023. The Author(s).

Références

Sci Rep. 2021 Sep 14;11(1):18194
pubmed: 34521881
Biochem Pharmacol. 2000 Jan 1;59(1):65-85
pubmed: 10605936
J Biol Chem. 1998 Jan 30;273(5):2895-904
pubmed: 9446600
Drug Metabol Drug Interact. 2012 Jan 31;27(1):3-8
pubmed: 22718620
Sci Rep. 2016 Aug 18;6:32009
pubmed: 27535013
Int J Mol Sci. 2022 Jan 28;23(3):
pubmed: 35163440
Biochim Biophys Acta. 2015 Aug;1853(8):1870-8
pubmed: 25960398
FEBS Open Bio. 2014 Sep 16;4:796-803
pubmed: 25349783
Chem Res Toxicol. 2020 Mar 16;33(3):742-750
pubmed: 31957441
J Biol Chem. 1999 Oct 1;274(40):28708-15
pubmed: 10497241
Int J Mol Sci. 2019 Sep 24;20(19):
pubmed: 31554340
Crit Rev Eukaryot Gene Expr. 2008;18(3):207-50
pubmed: 18540824
Biol Chem. 2015 Dec;396(12):1357-67
pubmed: 26351913
FEBS Lett. 2022 Aug;596(16):2056-2071
pubmed: 35735777
Genes Dev. 1999 Jul 1;13(13):1742-53
pubmed: 10398686
Mol Cell Biol. 2003 Nov;23(21):7920-5
pubmed: 14560034
J Biol Chem. 2003 Jan 24;278(4):2677-85
pubmed: 12431985
Arch Biochem Biophys. 2001 May 15;389(2):207-17
pubmed: 11339810
Chem Res Toxicol. 2008 Jan;21(1):102-16
pubmed: 18076143
Cells. 2018 Nov 21;7(11):
pubmed: 30469340
J Biol Chem. 1995 Nov 3;270(44):26292-302
pubmed: 7592839
Mol Cell Biol. 1999 Feb;19(2):1218-25
pubmed: 9891056
Mol Pharmacol. 2000 Jan;57(1):82-92
pubmed: 10617682
Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):
pubmed: 34210797
Curr Opin Cell Biol. 2019 Jun;58:50-60
pubmed: 30826604
Immunology. 2009 Jul;127(3):299-311
pubmed: 19538249
Antiviral Res. 2013 Sep;99(3):301-6
pubmed: 23769930
Int J Mol Sci. 2018 Dec 05;19(12):
pubmed: 30563036
Mol Cell Biol. 1998 Feb;18(2):978-88
pubmed: 9447995
Biochem Biophys Res Commun. 2004 Apr 30;317(2):545-50
pubmed: 15063792
J Biol Chem. 1988 Sep 25;263(27):13802-5
pubmed: 2843537
Oncotarget. 2017 May 30;8(22):36658-36663
pubmed: 28525368
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
Int J Mol Sci. 2020 Sep 16;21(18):
pubmed: 32947781
J Biochem. 2000 Mar;127(3):503-9
pubmed: 10731723
Toxicol Sci. 2011 Nov;124(1):1-22
pubmed: 21908767
Nat Rev Cancer. 2005 Feb;5(2):113-25
pubmed: 15660110
Antioxidants (Basel). 2020 Dec 12;9(12):
pubmed: 33322705
J Biol Chem. 1999 May 7;274(19):13519-24
pubmed: 10224120
J Exp Med. 2009 Jan 16;206(1):43-9
pubmed: 19114668
ACS Chem Biol. 2011 Jul 15;6(7):700-8
pubmed: 21469738
Structure. 2017 Jul 5;25(7):1025-1033.e3
pubmed: 28602820
Cell Commun Signal. 2021 May 22;19(1):60
pubmed: 34022911
FEBS J. 2015 Feb;282(3):445-62
pubmed: 25429850
J Biomol Screen. 2011 Feb;16(2):192-200
pubmed: 21297106
Arch Toxicol. 2018 Mar;92(3):1151-1160
pubmed: 29164305
J Toxicol. 2013;2013:279829
pubmed: 24454361
Pharmacol Rev. 2015;67(2):259-79
pubmed: 25657351
Mol Pharmacol. 2010 Feb;77(2):195-201
pubmed: 19917880
Sci Rep. 2016 Mar 18;6:23138
pubmed: 26988202

Auteurs

Rashad Haidar (R)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany. Rashad.Haidar@bfr.bund.de.
Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany. Rashad.Haidar@bfr.bund.de.

Reneh Shabo (R)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Marie Moeser (M)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Andreas Luch (A)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Department of Biology, Chemistry and Pharmacy, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.

Josephine Kugler (J)

Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH